Richard G Marlink
Overview
Explore the profile of Richard G Marlink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu K, Farahani M, Mashamba T, Mawela M, Joseph J, van Schaik N, et al.
AIDS
. 2014 Aug;
28(15):2259-68.
PMID: 25115319
Objective: To evaluate the safety of combination antiretroviral therapy (ART) in conception and pregnancy in different health systems. Design: A pilot ART registry to measure the prevalence of birth defects...
2.
McDonald B, Moyo S, Gabaitiri L, Gaseitsiwe S, Bussmann H, Koethe J, et al.
AIDS Res Hum Retroviruses
. 2013 Apr;
29(7):993-9.
PMID: 23590237
Elevated serum levels of inflammatory biomarkers have been associated with increased mortality and morbidity among HIV-infected individuals receiving combination antiretroviral therapy (cART) in European and U.S. cohorts. Few similar data...
3.
Stephens L, Bachhuber M, Seloilwe E, Gungqisa N, Mmelesi M, Bussmann H, et al.
J AIDS HIV Res
. 2013 Jan;
4(6):159-164.
PMID: 23275859
Students at the University of Botswana, an at-risk group, have previously been shown to have high levels of risky sexual behavior despite widespread knowledge that these behaviors might lead to...
4.
Moyo S, Bussmann H, Mangwendeza P, Dusara P, Gaolathe T, Mine M, et al.
J Antivir Antiretrovir
. 2012 Oct;
3(4):45-48.
PMID: 23087782
BACKGROUND: Nucleoside reverse-transcriptase inhibitors (NRTIs) are a major component of combination antiretroviral therapy (cART) worldwide but they have been associated with mitochondrial toxicities, with one of the most significant being...
5.
Wester C, Eden S, Shepherd B, Bussmann H, Novitsky V, Samuels D, et al.
AIDS Res Hum Retroviruses
. 2012 May;
28(8):759-65.
PMID: 22540188
Nucleoside analogue reverse transcriptase inhibitors are an integral component of combination antiretroviral treatment regimens. However, their ability to inhibit polymerase-γ has been associated with several mitochondrial toxicities, including potentially life-threatening...
6.
Wester C, Stitelman O, DeGruttola V, Bussmann H, Marlink R, van der Laan M
AIDS Res Hum Retroviruses
. 2012 Feb;
28(9):981-8.
PMID: 22309114
The Tshepo study was the first clinical trial to evaluate outcomes of adults receiving nevirapine (NVP)-based versus efavirenz (EFV)-based combination antiretroviral therapy (cART) in Botswana. This was a 3 year...
7.
Wester C, Koethe J, Shepherd B, Stinnette S, Rebeiro P, Kipp A, et al.
AIDS
. 2011 May;
25(12):1471-9.
PMID: 21572309
Objective: To compare incidence and distribution of non-AIDS-defining events (NADEs) among HIV-1-infected adults receiving combination antiretroviral therapy (cART) in urban sub-Saharan African versus United States settings. Design: Retrospective cohort analysis...
8.
Bussmann H, de la Hoz Gomez F, Roels T, Wester C, Bodika S, Moyo S, et al.
AIDS Res Hum Retroviruses
. 2010 Nov;
27(4):365-72.
PMID: 21034246
The emergence and spread of transmitted drug resistance (TDR) poses a major threat to the success of the rapidly expanding antiretroviral treatment (ART) programs in resource-limited countries. The World Health...
9.
Do N, Phiri K, Bussmann H, Gaolathe T, Marlink R, Wester C
AIDS Res Hum Retroviruses
. 2010 Jun;
26(6):685-91.
PMID: 20518649
As increasing numbers of persons are placed on potentially life-saving combination antiretroviral therapy (cART) in sub-Saharan Africa, it is imperative to identify the psychosocial and social factors that may influence...
10.
Wester C, Bussmann H, Koethe J, Moffat C, Vermund S, Essex M, et al.
HIV Ther
. 2010 Feb;
3(5):501-526.
PMID: 20161344
Numerous national public initiatives offering first-line combination antiretroviral therapy (cART) for HIV infection have commenced in sub-Saharan Africa since 2002. Presently, 2.1 million of an estimated seven million Africans in...